Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash & Equivalents: 2017-2024

Historic Cash & Equivalents for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $24.6 million.

  • Aclaris Therapeutics' Cash & Equivalents fell 47.00% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 47.00%. This contributed to the annual value of $24.6 million for FY2024, which is 38.39% down from last year.
  • Aclaris Therapeutics' Cash & Equivalents amounted to $24.6 million in FY2024, which was down 38.39% from $39.9 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Cash & Equivalents registered a high of $45.3 million during FY2022, and its lowest value of $22.1 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $39.9 million (2023), whereas its average is $36.6 million.
  • In the last 5 years, Aclaris Therapeutics' Cash & Equivalents plummeted by 38.61% in 2020 and then skyrocketed by 65.55% in 2022.
  • Aclaris Therapeutics' Cash & Equivalents (Yearly) stood at $22.1 million in 2020, then grew by 23.96% to $27.3 million in 2021, then soared by 65.55% to $45.3 million in 2022, then decreased by 11.92% to $39.9 million in 2023, then plummeted by 38.39% to $24.6 million in 2024.